Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress

veloping PAD.

* Further bolstered Vermillion's intellectual property by advancing

the Company's license agreement with Stanford University to an

exclusive level. The license from Stanford covers the development

and commercialization of a biomarker panel used to assess the risk

of PAD.

* Hosted a roundtable teleconference focusing on Vermillion's PAD

diagnostic program and the need for improved detection of this

life- and limb-threatening condition. The teleconference featured

keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at

Stanford University, whose research forms the basis of Vermillion's


* Conducted market-development activities, including working with the

PAD Coalition and implementing an online physician survey to gather

market-based information, helping to define the Company's

commercialization strategy and broaden future clinical use of


-- Ovarian Cancer Diagnostic Program

* Continued to make progress with the clinical study evaluating OVA1

and plan to submit to the FDA in the second quarter.

* Presented data from several studies demonstrating the benefits of

the Company's ovarian cancer diagnostic test programs at the

Society of Gynecologic Oncologists' (SGO) 39th Annual Meeting on

Women's Cancer. The data suggest that use of Vermillion's tests

could help better identify women with early-stage ovarian cancer

and improve detection.

* Received the distinguished SGO Basic Science Poster Award for its

abstract, "Prospective independent validation of a marker panel for

distinguishing benign from malignant pelvic masses."

-- Hematology Diagnostic Program

* Reporte

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
(Date:10/8/2015)... ALS Association, in partnership with Prize4Life, is pleased to ... technology solutions for people living with ALS. ... sclerosis) is a progressive neurodegenerative disease that affects neurons ... Eventually, people with ALS lose the ability to initiate ... paralysis and death within two to five years of ...
(Date:10/8/2015)... ... 2015 , ... Talon Innovations, a provider of Precision Machined Products ... it is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in ... Talon Innovations was recognized as a nominee for this competitive award. , The ...
(Date:10/7/2015)... Mass. , Oct. 7, 2015 ... announced the start of the Boston Scientific Connected ... encourage advancements in the use of remote patient monitoring ... engineers, designers and entrepreneurs can submit their ideas and ... site ( ). Cambridge, MA ...
(Date:10/7/2015)... Oct. 7, 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of targeted antiviral ... offering of 5,000,000 shares of its common stock and ... Company,s common stock at a fixed combined price to ... and warrants will be issued separately.  The warrants will ...
Breaking Biology Technology:
... Suggests that Understanding the Fundamental Mechanism of Angiogenesis ... VEGF - AAmgen Launches Angiogenesis Website THOUSAND OAKS, ... AMGN ) today announced that results from several ... be presented at the 2009 American Association for ...
... automating their environmental monitoring processes using MODA-EM™ , ... ... -- The Parenteral Drug Association (PDA) is hosting their annual ... Red Rock Casino and Resort. During this event, MODA Technology ...
... April 16 Cord Blood America, Inc. (OTC Bulletin ... company ( ) focused ... to families nationwide and internationally, said today that revenues ... increased 8.7 percent, or $0.3 million, to $3.4 million ...
Cached Biology Technology:
(Date:9/26/2015)... -- Results of a TactioRPM pilot project in a ... Stanford Medicine X Conference. In a presentation titled ... Devices and Pharmacogenomics", Roger Simard , Pharmacist ... senior patients equipped with connected health devices and ... TactioRPM remote patient monitoring platform were empowered to ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... quite delivered upon previous expectations of revenues, consumer adoption ... breakthrough year in which wearables begin to achieve that ... of the main reasons is the entrance of Apple ... the SmartWatches market, but the overall size of the ...
(Date:9/8/2015)... -- Affectiva, global leader in emotion-sensing and analytics, announces ... data solution, and version 2.0 of its emotion-sensing ... and patented science, these new offerings provide unique ... such as market research, gaming, media and entertainment, ... HR, automotive, robotics, healthcare and wearables. ...
Breaking Biology News(10 mins):
... a venture once thought to lie outside the reach ... Israel Deaconess Medical Center have captured and sequenced tiny ... rex. The protein fragments—seven in all—appear to most closely ... day chickens, lending support to a recent and still ...
... disease regardless of the stage at time of diagnosis. ... of ductal adenocarcinoma associated with cystic lesions that can ... 50 percent long-term survival rate. Why cystic ductal pancreatic ... mutations as the more common and deadly type of ...
... mesothelioma ?a form of cancer associated with asbestos exposure ?have ... two cancer drugs, a large multicenter study finds. , Mesothelioma, ... the lining of the lungs, heart and abdomen, is associated ... , In the study, patients receiving pemetrexed and cisplatin ?along ...
Cached Biology News:
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: